RT Journal Article
SR Electronic
T1 Effect of Breast Cancer Adjuvant Therapies on Potential Biomarkers of Pulmonary Inflammation
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 4993
OP 5002
VO 32
IS 11
A1 MARIA PIPERIS
A1 XENI PROVATOPOULOU
A1 ALEXANDROS SAGKRIOTIS
A1 ELENI KALOGERA
A1 EMMANOUIL AMPATZOGLOU
A1 GEORGE C. ZOGRAFOS
A1 ELENI ATHANASIOU
A1 ANTONIA GOUNARIS
YR 2012
UL http://ar.iiarjournals.org/content/32/11/4993.abstract
AB Background: The aim of this study was to investigate the effect of breast cancer adjuvant therapies on the levels of circulating surfactant protein-D (SP-D), C-Reactive protein (CRP) and soluble receptor for advanced glycation end-products (sRAGE), as potential biomarkers of subclinical pulmonary inflammation. Materials and Methods: The soluble molecules were serially determined in 38 patients, prior to the initiation of radiation therapy (RT) and during adjuvant treatment, using immunoassays. Results: Significantly higher levels of all three biomarkers were observed in patients prior to the initiation of RT compared to healthy controls (CRP: p<0.001, SP-D: p<0.05, sRAGE: p<0.05). SP-D levels exhibited a gradual increase after RT and during follow-up (p<0.005). Patients treated with a combination of RT and hormonal therapy presented a significant, but less pronounced, increase in SP-D and a significant decrease in CRP compared to those who did not receive hormonal therapy (p=0.0428 and p=0.0116, respectively). Patients treated with a combination of RT and trastuzumab presented a significant increase in SP-D levels (p=0.0310). Conclusion: The average rate of change in the levels of circulating SP-D and CRP during postoperative irradiation and adjuvant hormonal therapy suggests that the combined therapeutic regiment may potentially exert important anti-inflammatory effects on the lung. On the contrary, combined administration of RT and trastuzumab is likely to induce or provoke pulmonary inflammation.